Nexalin Technology, Inc. Warrant - NXLIW STOCK NEWS

Nexalin Technology announces the formation of a Military & Government Advisory Board to support its deep-brain stimulation devices within U.S. government agencies. The Advisory Board will work closely with the company in formulating strategic direction and implementing commercialization. The company welcomes David Lasseter, former Deputy Assistant Secretary of Defense for Policy, as the leader of the Advisory Board.

Nexalin Technology reports positive results in migraine and depression clinical studies, indicating potential therapeutic benefits of its neurostimulation device. The migraine study showed a significant reduction in pain frequency and degree, with a strong safety profile. The depression study demonstrated better remission and response rates compared to sham treatment. Mental health conditions are increasing globally. The migraine and depression markets are estimated at $3.9 billion and $11.2 billion, respectively.

Nexalin Technology, Inc. announced that its CEO, Mark White, will be participating in a live interview with the 'Big Biz Show' to discuss recent developments and upcoming milestones regarding their non-invasive, frequency-based, deep-brain stimulation medical devices for treating mental health and addiction disorders. The interview will be aired on cable TV, streaming services, and radio in 175 countries, with podcasts available on various platforms.

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) announced the formation of 'Nexalin America' to collaborate with U.S. government agencies for the use of its non-invasive deep-brain stimulation devices in treating PTSD, traumatic brain injury, anxiety, depression, and insomnia. The company has hired industry and government affairs veteran, Ryan Kane, to lead this initiative.

Nexalin Technology, Inc. announces that their abstract on traumatic brain injury (TBI) has been accepted for presentation at the 2023 Military Health System Research Symposium. The abstract describes a study using MEG to assess neuronal changes in veterans with combat-related mTBI after treatment with Nexalin's non-invasive deep-brain stimulation device. The reduction of hyperactivity in mTBI suggests the treatment can be effective without side effects. The study builds on prior data in insomnia, which has shown a high correlation with TBI.

Nexalin Technology has formed a joint venture with Wider Come Limited to develop and distribute its second generation transcranial Alternating Current Stimulation (tACS) devices in China and the Asia Pacific region. Wider will also fund and conduct four clinical trials using Nexalin's devices for the treatment of insomnia, depression, and other indications.

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update on March 27, 2023, highlighting progress in clinical trials for new neurostimulation devices aimed at treating mental health disorders. The Gen-2 and Gen-3 devices are expected to improve treatment efficacy without medication. Revenue for 2022 reached $1.3 million, a significant increase from $0.1 million in 2021, primarily due to more device sales. While operating expenses decreased to $2.8 million from $6.1 million, the net loss narrowed to $1.7 million per share. The company reports having $7.0 million in liquidity for future operations.

Nexalin Technology announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical, and Regulatory. Nketiah brings over 23 years of experience in regulatory affairs and clinical operations, specifically with the FDA. His expertise will support the company in accelerating FDA clearance for its Generation 2 and Generation 3 neurostimulation devices, aimed at improving healthcare outcomes for mental and neurodegenerative illnesses. The Gen-2 device is designed to penetrate deeper into the brain using an advanced waveform, while the Gen-3 prototype will utilize a virtual-clinic model for treatment.

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update emphasizing its advancements in neurostimulation devices aimed at combating mental health disorders. The company is enhancing its Gen-1 device to a more powerful Gen-2 model with a waveform increase from 4 milliamps to 15 milliamps, expected to improve treatment efficacy. Plans for FDA submissions and clinical trials are outlined, including a strategy for addressing Major Depressive Disorder. Additionally, Nexalin reports progress with its devices in China and a recent white paper supporting its technology's effectiveness for anxiety treatment.